Defiance's autism ETF carries a 0.79% fee and an equal-weighted clinical-trial screen

The Defiance Autism Impact ETF has traded since June 1 under the ticker ASD, a developed-market portfolio of companies its index provider judges to play a material role in neurodiversity care, at a 0.79% gross expense ratio, and it is billed as the first autism-focused ETF. The advisor-facing case for it was made at the end of September in an ETF Trends discussion among Kirsten Chang, a senior industry analyst at VettaFi; Jane Edmondson, who heads index product strategy there; and Brendan Cavanaugh, Defiance's chief strategy officer. What the three laid out is an ecosystem argument: the fund is built to hold the ecosystem rather than the diagnosis.

The numbers are big and, for an equity investor, slippery: annual societal cost of autism care in the United States was projected to reach $461 billion by 2025, lifetime costs are estimated at $3.2 million per person, and more than 85% of people diagnosed with autism experience at least one co-occurring physical, neurological or psychological condition. That comorbidity is the part a public portfolio can reach today, because prescriptions, devices and clinical services already exist there. Cost is not revenue. Much of the spending runs through public programs, and the paying mechanisms are scattered across Medicaid, the Affordable Care Act, federal mental health parity rules and autism coverage mandates now in place in 46 states.

The discussion attributes the rise in diagnoses to broader awareness, improved screening and expanded diagnostic practice, a demand curve whose shape depends on how the condition gets counted. At its center, the treatment map is still nearly blank: there are no FDA-approved drugs for the core symptoms of autism spectrum disorder, so care concentrates in behavioral, educational and supportive interventions, and federal support continues through the Autism CARES Act, which directs between $250 million and $350 million a year to the National Institutes of Health through 2029.

The index ASD tracks works around that emptiness: VettaFi screens developed-market companies on clinical trial activity, product indications and revenue exposure, requires at least $250 million in market capitalization plus liquidity requirements, and equal-weights whatever qualifies. Equal weighting, per Defiance, limits the influence of large pharmaceutical companies and spreads exposure across large-, mid- and small-cap stocks. North America is about 58% of the index, and the book reconstitutes twice a year and rebalances quarterly.

A developed-market mandate that runs close to three-fifths North American keeps most of the portfolio in the market whose payment terms—state mandates, Medicaid, the ACA—occupy most of the discussion. Equal weighting plus a $250 million floor also pushes the differentiation into the small- and mid-cap sleeve, since no mega-cap that clears the floor can dominate the book.

That weighting choice carries more of the methodology than the screens do: a cap-weighted portfolio filtered on revenue exposure would drift toward whichever large health-care company sells most into the space, and within a few reconstitutions the fund would be a sector fund wearing a patient-population label, while equal weights, refreshed at the two annual reconstitutions, keep the smallest qualifying companies from becoming rounding errors. The screens cannot manufacture approved therapies. Since clinical trial activity is one of the three factors and no drug is approved for core symptoms, the pipeline is doing work the commercial line cannot yet do, which makes ASD in part a wager on readouts and on which trial-stage names still look material the next time the screen runs. Trial-stage exposure has a precedent: THNR's September rebalance moved two names into the 20-stock index of a $5.8 million fund whose return still rides on Eli Lilly.

Defiance plans to donate 100% of net advisory profits during the fund's first two years and at least 50% thereafter to autism care and research organizations, so for two years the fund's charitable output and its commercial output are the same number—an unusual structure for a product that has to be explained before it can be bought. The material gives the gross expense ratio and no net figure, so what survives the fund's own costs is not something the coverage settles.

ASD also sits alongside another narrow mandate from the same issuer, three months apart: Defiance's Israel fund, ISRL, listed on Sept. 1, and it went local, tracking Tel Aviv-listed names instead of Israel-heavy multinationals and turning a country ETF into a direct local-market wager. ASD takes the other construction path, spreading a single theme across developed markets behind a $250 million market-cap floor. Two launches built on a screen rather than a sector label say as much about how this issuer reads demand for narrow exposures as the theses themselves.

Whether any of it reaches a model portfolio is a separate question, and in a market where shelf space rather than ticker count is the scarce asset, a fund whose category has to be taught first starts behind the plain-vanilla launch beside it on the platform—ETF Trends has paired its September discussion with a companion piece titled "Inside ASD: The Story Behind the First Autism ETF," which suggests the education effort is being run in public. For two years the fund's advisory profit is pledged away, so the case for running ASD likely rests on distribution and firm-level scale rather than the fund's own margin; this publication's records put Defiance at about $3.9 billion in regulatory assets as of late September. The open question is whether an equal-weighted screen with a $250 million floor can hold the core of the theme, or whether, absent an approved therapy for core symptoms, ASD's largest exposures end up being the comorbidity economy—the part of the care ecosystem that already has products to sell.